NYSE:DHR
Danaher Corporation Stock News
$248.76
+1.36 (+0.550%)
At Close: May 07, 2024
Exlusive: Why Abcam founder believes Danaher's acquisition offer falls short
08:46am, Monday, 16'th Oct 2023
In an exclusive interview with Thomas Warner (TW) of Proactive London, Dr Jonathan Milner (JM), the founder of life sciences company Abcam PLC (NASDAQ:ABCM), discusses why he believes the $24 per shar
IPOs are out of fashion. Here's what companies are doing instead.
11:39am, Friday, 06'th Oct 2023
While the current deal landscape on Wall Street remains low on M&A, initial public offerings (IPOs), and other transactions, corporate spinoffs are chugging along.
Veralto: Thoughts On The Danaher Spinoff
01:14pm, Monday, 02'nd Oct 2023
Veralto Corporation, the former Environmental & Applied Solutions segment of Danaher Corporation, has started trading as a publicly traded entity. Veralto is a $5 billion business focused on water and
Why Shares of Danaher Are Down Monday
12:21pm, Monday, 02'nd Oct 2023
Danaher's revenues declined in the second quarter. Its spinoff, Veralto, began trading on Monday.
Veralto stock to join S&P 500, Kohl's to join S&P SmallCap 600
05:43pm, Thursday, 28'th Sep 2023
Danaher Corp. DHR, -0.10% spinoff Veralto Corp. VLTO.WI, +5.02% will be added to the S&P 500 before trading Monday, when it replaces DXC Technology Co. DXC, +0.59%, which in turn will move to the S&P
Danaher Schedules Third Quarter 2023 Earnings Conference Call
04:15pm, Tuesday, 26'th Sep 2023
WASHINGTON, Sept. 26, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2023 on Tuesday, October 24, 202
Danaher Lowers Price Of Tuberculosis Test After Pressure Campaign
03:53pm, Tuesday, 19'th Sep 2023
Popular novelist and YouTuber John Green as well as international health nonprofits had been running a weeklong pressure campaign against the company.
The 7 Most Undervalued Safe Stocks to Buy in September 2023
09:47pm, Wednesday, 13'th Sep 2023
September — widely regarded as the “worst month for the stock market” — is living up to its reputation. In fact, the S&P 500 is down 1% since August, in line with its average 1.1% monthly decl
The 3 Most Undervalued Healthcare Stocks to Buy in September 2023
11:04am, Wednesday, 13'th Sep 2023
Healthcare is a sector that has underperformed the broader stock market this year. The S&P 500 Health Care Sector Index is down over 2.50% year-to-date versus a 17% gain in the benchmark S&P 500 index
The 3 Best Pharma Stocks to Buy Now: September 2023
09:14am, Friday, 08'th Sep 2023
The pharmaceutical sector will always be a sector in constant evolution and growth. As technology advances, the companies that make life in this sector will always be applying it, as well as implement
Here's Why You Should Steer Clear of Danaher (DHR) Stock Now
02:17pm, Tuesday, 05'th Sep 2023
Lower demand for COVID-related products, raw material cost inflation and foreign currency headwinds weigh on Danaher's (DHR) operations.
Danaher and Veralto to Webcast Investor and Analyst Meeting
06:00pm, Thursday, 31'st Aug 2023
WASHINGTON , Aug. 31, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of Veralto's Investor and Analyst Meeting on September 6, 2023 beginning at approximately 12:0
Gurus' Top Stock Picks for the 2nd Quarter
03:45pm, Thursday, 31'st Aug 2023
The second quarter of 2023 was characterized by moderating inflation and signs the economy remains resilient despite interest rates rising. As such, the S&P 500 gained 7.90% during the three months en
When ChatGPT Misses the Mark: 3 Stocks It Got Very Wrong
07:00am, Thursday, 31'st Aug 2023
Artificial Intelligence ( AI ) has received incredible attention this year due to the public release of OpenAI's ChatGPT. Its profound capabilities have successfully captured the imaginations of a s
Danaher: A Lost Year
06:37pm, Wednesday, 30'th Aug 2023
Danaher Corporation benefited from the Covid-19 period and saw strong growth, aided by bolt-on deals and reasonable leverage. The company acquired the biopharma business from General Electric in a $21